Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced CRS.
Key highlights
– Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo model
– Data strengthens and facilitates the expansion of patent applications for POLB 001 in cancer immunotherapy-induced CRS
– Independent Advisory Board supportive of POLB 001’s potential to both prevent and treat cancer immunotherapy-induced CRS